ACRX AcelRx Pharmaceuticals Inc.
2.21
0 0%
Previous Close
2.21
Open
2.2
Price To Book
-9.61
Market Cap
175,552,548
Shares
79,435,542
Volume
313,505
Short Ratio
Av. Daily Volume
722,315
Drug Information
Drug catalyst information is displayed when you hover over / tap on the stage bar graph.
Phase 3 data released August 15 2016
ARX-04 (SAP302)
Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury
FDA Approval announced November 2, 2018.
DSUVIA (ARX-04)
Moderate-to-severe acute pain following a surgical procedure
CRL Jul 26 2014. NDA resubmission timing to be known in 2H 2019.
Zalviso
Post-operative pain following open abdominal surgery and hip or knee replacement surgery